Positive Results In Lyrica Study for Fibromyalgia

Topic: Fibromyalgia
- Content Writer/Editor for Disabled World
Published: 2011/07/06 - Updated: 2022/02/18
Contents: Summary - Introduction - Main Item - Related Topics

Synopsis: Pfizer Japan Inc. announces positive results for Lyrica in phase 3 study of patients with fibromyalgia. Fibromyalgia is a common syndrome in which a person has long-term, body-wide pain and tenderness in the joints, muscles, tendons, and other soft tissues. Fibromyalgia has also been linked to fatigue, sleep problems, headaches, depression, and anxiety. Lyrica capsules CV is the first FDA-approved treatment for the management of fibromyalgia in the U.S. It has been approved for other conditions since 2004.

Introduction

Pharmaceutical giant Pfizer, Inc.'s Japan unit, Pfizer Japan, Inc., announced positive top-line results for Lyrica in phase 3 study of patients with fibromyalgia in Japan. The company said that further analysis' will be conducted on these initial results.

Main Item

Lyrica (pregabalin) capsules CV got expanded approval in Japan since October 2010 to treat peripheral neuropathic pain, but not to treat fibromyalgia. It was the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd. It was also approved in Japan of for the treatment of postherpetic neuralgia in April 2010.

Fibromyalgia is a common syndrome in which a person has long-term, body-wide pain and tenderness in the joints, muscles, tendons, and other soft tissues. Fibromyalgia has also been linked to fatigue, sleep problems, headaches, depression, and anxiety.

Fibromyalgia is a disabling disorder that adversely affects quality of life in these afflicted patients. However, fibromyalgia has historically been considered either a musculoskeletal disease or neuropsychiatric condition.

According to Pfizer Japan, the 16-week A0081208 Lyrica phase 3 study, was a randomized, double-blind, placebo-controlled, parallel group, multi-center study, comparing pregabalin and placebo in subjects with with fibromyalgia.

"We are pleased with the top-line results of this study and look forward to more fully understanding the potential benefits that Lyrica may bring to fibromyalgia patients in Japan," said Akihisa Harada, vice president, Head of Development Japan, at Pfizer Japan.

In the study, which was conducted in 45 investigative sites in Japan, pregabalin was flexibly dosed as 300-450mg/day or dosed twice daily. A total of 501 subjects were enrolled in the study.

The most common adverse events observed in lyrica-treated patients were somnolence, dizziness, weight increase, constipation, feeling abnormal, edema peripheral and blurred vision.

Anti-epileptic drugs Lyrica is currently approved in 110 countries and regions globally. In the U.S., lyrica capsules CV is approved to treat diabetic nerve pain, pain after shingles, fibromyalgia and partial onset seizures in adults with epilepsy who take one or more drugs for seizures. It is not approved to treat central neuropathic pain in the U.S.

Lyrica capsules CV is the first FDA-approved treatment for the management of fibromyalgia in the U.S. It has been approved for other conditions since 2004.

Explore Related Topics

1 - - A pioneering blood sample test enables fibromyalgia to be identified quicker and precisely.

2 - - First RNA-Based Blood Test to Detect Fibromyalgia Introduced by Data Science Company IQuity accurately identifies gene expression pattern consistent with fibromyalgia syndrome, reducing need to rule out other conditions and speeding time to diagnosis.

3 - - IMC-1 oral medication proves highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

4 - - Article takes a look at some of the similarities between osteoarthritis and fibromyalgia symptoms and pain.

5 - - Compares Medical Marijuana against Cymbalta (Duloxetine), Lyrica (Pregabalin), and Savella (Milnacipran) - the three drugs approved for treatment of fibromyalgia..

Complete List of Related Information

Page Information, Citing and Disclaimer

Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): Langtree, I. C. (2011, July 6 - Last revised: 2022, February 18). Positive Results In Lyrica Study for Fibromyalgia. Disabled World. Retrieved October 7, 2024 from www.disabled-world.com/health/fibromyalgia/lyrica-study.php

Permalink: <a href="https://www.disabled-world.com/health/fibromyalgia/lyrica-study.php">Positive Results In Lyrica Study for Fibromyalgia</a>: Pfizer Japan Inc. announces positive results for Lyrica in phase 3 study of patients with fibromyalgia.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.